Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 N0147: a randomized phase III trial of oxaliplatin plus 5-fluorouracil/leucovorin with or without cetuximab after curative resection of stage III colon cancer.

× No keyword cloud information.

12 in total

1. Design of clinical trials for biomarker research in oncology.

Authors: Sumithra J Mandrekar; Daniel J Sargent
Journal: Clin Investig (Lond) Date: 2011-12

Review 2. Adjuvant therapy for stages II and III colon cancer: risk stratification, treatment duration, and future directions.

Authors: U Bender; Y S Rho; I Barrera; S Aghajanyan; J Acoba; P Kavan
Journal: Curr Oncol Date: 2019-11-01 Impact factor: 3.677

Review 3. Targeted therapeutic agents for colorectal cancer.

Authors: Cheng E Chee; Frank A Sinicrope
Journal: Gastroenterol Clin North Am Date: 2010-09 Impact factor: 3.806

4. A Statistical Method for Association Analysis of Cell Type Compositions.

Authors: Licai Huang; Paul Little; Jeroen R Huyghe; Qian Shi; Tabitha A Harrison; Greg Yothers; Thomas J George; Ulrike Peters; Andrew T Chan; Polly A Newcomb; Wei Sun
Journal: Stat Biosci Date: 2021-09-15

5. Early-Onset Colorectal Cancer: The Mystery Remains.

Authors: Cathy Eng; Howard Hochster
Journal: J Natl Cancer Inst Date: 2021-08-18 Impact factor: 11.816

6. An Electronic Information Kiosk for Enhancing Patient Accrual for Cancer Clinical Trials: A Pilot and Feasibility Study.

Authors: Morgan D Black; Lilian Esene; Richard McClelland; Heather Mayer; Stephen Welch; Glenn Bauman; Theodore Vandenberg
Journal: Cureus Date: 2022-05-18

7. Clinical predictors of severe cetuximab-induced rash: observations from 933 patients enrolled in north central cancer treatment group study N0147.

Authors: Aminah Jatoi; Erin M Green; Kendrith M Rowland; Daniel J Sargent; Steven R Alberts
Journal: Oncology Date: 2009-07-22 Impact factor: 2.935

8. Impact of age on the efficacy of newer adjuvant therapies in patients with stage II/III colon cancer: findings from the ACCENT database.

Authors: Nadine J McCleary; Jeffrey A Meyerhardt; Erin Green; Greg Yothers; Aimery de Gramont; Eric Van Cutsem; Michael O'Connell; Christopher J Twelves; Leonard B Saltz; Daniel G Haller; Daniel J Sargent
Journal: J Clin Oncol Date: 2013-06-03 Impact factor: 44.544

9. Genetic Variant Associated With Survival of Patients With Stage II-III Colon Cancer.

Authors: Kathryn L Penney; Barbara L Banbury; Stephanie Bien; Tabitha A Harrison; Xinwei Hua; Amanda I Phipps; Wei Sun; Mingyang Song; Amit D Joshi; Steven R Alberts; Carmen J Allegra; James Atkins; Linda H Colangelo; Thomas J George; Richard M Goldberg; Peter C Lucas; Suresh G Nair; Qian Shi; Frank A Sinicrope; Norman Wolmark; Greg Yothers; Ulrike Peters; Polly A Newcomb; Andrew T Chan
Journal: Clin Gastroenterol Hepatol Date: 2019-12-04 Impact factor: 11.382

10. A Phase II study of cetuximab (Erbitux) plus FOLFIRI for irinotecan and oxaliplatin-refractory metastatic colorectal cancer.

Authors: Dong Hoe Koo; Jae Lyun Lee; Tae Won Kim; Heung Moon Chang; Min Hee Ryu; Sung Sook Lee; Min Kyoung Kim; Sun Jin Sym; Jung Shin Lee; Yoon Koo Kang
Journal: J Korean Med Sci Date: 2007-09 Impact factor: 2.153